We consider the development strategies of dual-targeting CD19/CD20 [157], CD19/CD22 [158], and BCMA/CD38 CAR-T cells [159] in preclinical models and clinical trials of hematologic malignancies and multiple myeloma. The gene discussed is CD19; the disease is hematologic disorder.